sorafenib has been researched along with chitosan in 10 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (chitosan) | Trials (chitosan) | Recent Studies (post-2010) (chitosan) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 27,648 | 232 | 21,257 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, J; Dai, Z; Lan, Y; Tu, W; Wei, T; Zhao, B | 1 |
| Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH | 1 |
| Liang, Y; Su, Z; Yao, Y; Zhang, N | 1 |
| Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G | 1 |
| Han, HK; Kim, HY; Lee, SH; Song, JG; Zhao, M | 1 |
| Jahanian, A; Raghami, F; Rostami, M; Varshosaz, J | 1 |
| Hou, T; Wang, T; Yin, X; Zhang, J; Zhang, N | 1 |
| Chen, A; Cheng, CH; Chou, CM; Chu, CY; Lee, YA; Liu, CY; Liu, EH; Mi, FL; Wang, CY | 1 |
| Awasthi, R; Dahiya, M; Dua, K; Dureja, H; Sharma, S; Yadav, JP | 1 |
| Albalawi, F; Fakurazi, S; Hussein, MZ; Masarudin, MJ | 1 |
10 other study(ies) available for sorafenib and chitosan
| Article | Year |
|---|---|
Electrochemical monitoring of an important biomarker and target protein: VEGFR2 in cell lysates.
Topics: Animals; Biosensing Techniques; Cell Line; Chitosan; Electrochemical Techniques; Endothelial Cells; Graphite; Immunoassay; Macaca mulatta; Niacinamide; Oxidation-Reduction; Phenothiazines; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retina; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Kidney Neoplasms; Kinetics; Lactic Acid; Liposomes; Nanoparticles; Nanotechnology; Niacinamide; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Sorafenib; Technology, Pharmaceutical | 2015 |
pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cations; Cell Proliferation; Chitosan; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2015 |
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chitosan; Delayed-Action Preparations; Disaccharides; Drug Synergism; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Lung Neoplasms; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Porosity; Rats; Silicon Dioxide; Sorafenib; Triterpenes; Ursolic Acid | 2017 |
Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Survival; Chitosan; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Liposomes; Male; Niacinamide; Phenylurea Compounds; Polymethacrylic Acids; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Sorafenib | 2018 |
PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Membrane Permeability; Cell Survival; Chitosan; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Emulsions; Hep G2 Cells; Humans; Liver Neoplasms; Nanocapsules; Octreotide; Polyethylene Glycols; Sorafenib; Surface Properties | 2019 |
Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy.
Topics: Animals; Benzamides; Carcinoma, Hepatocellular; Cell Survival; Chitosan; Drug Carriers; Humans; Immunotherapy; Liver Neoplasms; Macrophages; Mannose; Mice; Microscopy, Confocal; Nanoparticles; Protein Kinase Inhibitors; RAW 264.7 Cells; Sorafenib; Tissue Distribution | 2019 |
A low-molecular-weight chitosan fluorometric-based assay for evaluating antiangiogenic drugs.
Topics: Angiogenesis Inhibitors; Animals; Animals, Genetically Modified; Chitosan; Endothelial Cells; Green Fluorescent Proteins; Sorafenib; Zebrafish | 2023 |
Chitosan based sorafenib tosylate loaded magnetic nanoparticles: Formulation and in-vitro characterization.
Topics: Chitosan; Drug Carriers; Ferrosoferric Oxide; Humans; Magnetite Nanoparticles; Microscopy, Atomic Force; Nanoparticles; Particle Size; Sorafenib | 2023 |
Fabrication and characterization of nanodelivery platform based on chitosan to improve the anticancer outcome of sorafenib in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chitosan; Drug Carriers; Humans; Liver Neoplasms; Nanoparticles; Sorafenib | 2023 |